Research Progress of New Substance Status of the Applicable Drug Based on Adverse Reactions of Brain Metabolites
10.3870/j.issn.1004-0781.2025.06.004
- VernacularTitle:基于改善脑代谢药物不良反应的适药新物态研究进展
- Author:
Wenwen WANG
1
;
Yanxiao JIA
;
Ming YAN
;
Dezhi YANG
;
Li GAO
;
Li ZHANG
;
Yang LYU
Author Information
1. 北京协和医学院·中国医学科学院药物研究所,药物晶型研究中心,晶型药物研究北京市重点实验室,北京 100050
- Publication Type:Journal Article
- Keywords:
Brain metabolism drugs;
Adverse drugs effects;
New state for pharmaceuticalsubstance;
Polymorphicdrugs;
Co-crystal drugs
- From:
Herald of Medicine
2025;44(6):862-867
- CountryChina
- Language:Chinese
-
Abstract:
The drugs used to improve brain metabolism mainly include ergotamine derivatives,GABA derivatives,vitamin B6 derivatives,neuropeptides,morpholines,hormones and other.However,these drugs may have adverse reactions during clinical application.This article focuses on the adverse effects of commonly used drugs for brain metabolism,and reviews the studies on the new state of pharmaceutical substances,such as drug combination,chiral resolution of isomers,crystal form of dominant drugs,co-crystal drugs and nanodrugs,with the aim of reducing adverse reactions.By summarizing the research on modifying the solid state of drugs to mitigate adverse reactions,this article provides new research insights for obtaining new drug with less adverse reaction and greater clinical value.
